Healthcare Aug 19, 2021 09:31 AM (GMT+8) · EqualOcean
EU billion health learned on the 19th that Saifu pharmaceutical, a pharmaceutical cro service platform, announced the completion of a round C financing of 300 million + yuan, which was led by CICC Qide fund under CICC capital, followed by GF Qianhe, Huakong investment and Baotai biology. The funds will be used to continuously promote the capacity-building, capacity expansion and team building of Saifu pharmaceutical's one-stop innovative pharmaceutical cro service platform. Founded in 2016, Saifu pharmaceutical covers professional and technical services such as pharmaceutical R & D consulting, drug screening, pharmaceutical preparations, pharmacological efficacy, model animals, drug metabolic analysis, non clinical safety evaluation, clinical biological sample testing, clinical phase I, pharmacovigilance, as well as general contracting customized development and innovative drug incubation investment business in Beijing, Shenzhen, Chengdu, Suzhou, Shenyang The United States has branches. In recent years, driven by the development of innovative drugs and the increasing cost of drug development in China, the domestic pharmaceutical cro industry is in a period of vigorous development. In the past two years, the development of innovative therapies such as gene therapy and cell therapy has entered the "fast lane", and the demand for relevant cros has become increasingly strong. At present, Saifu pharmaceutical has provided many enterprises with R & D services for innovative therapy technologies such as vaccines, nucleic acid drugs, gene therapy, ADC, cell therapy, multi antibody, oncolytic virus and so on.

This text is a result of machine translation.